Logo image of IPA

IMMUNOPRECISE ANTIBODIES LTD (IPA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:IPA - CA45257F2008 - Common Stock

2.07 USD
+0.14 (+7.25%)
Last: 9/3/2025, 8:24:29 PM
2.12 USD
+0.05 (+2.42%)
After Hours: 9/3/2025, 8:24:29 PM
Fundamental Rating

2

IPA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 57 industry peers in the Life Sciences Tools & Services industry. IPA may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, IPA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • IPA had negative earnings in the past year.
  • In the past year IPA has reported a negative cash flow from operations.
  • IPA had negative earnings in each of the past 5 years.
  • In the past 5 years IPA always reported negative operating cash flow.
IPA Yearly Net Income VS EBIT VS OCF VS FCFIPA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -68.03%, IPA is doing worse than 89.09% of the companies in the same industry.
  • With a Return On Equity value of -127.97%, IPA is not doing good in the industry: 83.64% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -68.03%
ROE -127.97%
ROIC N/A
ROA(3y)-49.16%
ROA(5y)-35.25%
ROE(3y)-84.68%
ROE(5y)-57.83%
ROIC(3y)N/A
ROIC(5y)N/A
IPA Yearly ROA, ROE, ROICIPA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100 -150 -200

1.3 Margins

  • Looking at the Gross Margin, with a value of 55.25%, IPA is in the better half of the industry, outperforming 65.45% of the companies in the same industry.
  • In the last couple of years the Gross Margin of IPA has remained more or less at the same level.
  • IPA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 55.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.87%
GM growth 5Y-0.67%
IPA Yearly Profit, Operating, Gross MarginsIPA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150 -200

More info and screens

2

2. Health

2.1 Basic Checks

  • IPA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • IPA has more shares outstanding than it did 1 year ago.
  • IPA has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for IPA is higher compared to a year ago.
IPA Yearly Shares OutstandingIPA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
IPA Yearly Total Debt VS Total AssetsIPA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

  • Based on the Altman-Z score of -0.35, we must say that IPA is in the distress zone and has some risk of bankruptcy.
  • IPA has a worse Altman-Z score (-0.35) than 76.36% of its industry peers.
  • IPA has a Debt/Equity ratio of 0.49. This is a healthy value indicating a solid balance between debt and equity.
  • IPA has a worse Debt to Equity ratio (0.49) than 63.64% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF N/A
Altman-Z -0.35
ROIC/WACCN/A
WACC10.11%
IPA Yearly LT Debt VS Equity VS FCFIPA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M

2.3 Liquidity

  • A Current Ratio of 2.08 indicates that IPA has no problem at all paying its short term obligations.
  • The Current ratio of IPA (2.08) is comparable to the rest of the industry.
  • IPA has a Quick Ratio of 1.85. This is a normal value and indicates that IPA is financially healthy and should not expect problems in meeting its short term obligations.
  • IPA has a Quick ratio (1.85) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.08
Quick Ratio 1.85
IPA Yearly Current Assets VS Current LiabilitesIPA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M

More info and screens

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 34.78% over the past year.
  • Looking at the last year, IPA shows a small growth in Revenue. The Revenue has grown by 0.01% in the last year.
  • The Revenue has been growing by 11.77% on average over the past years. This is quite good.
EPS 1Y (TTM)34.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.55%
Revenue 1Y (TTM)0.01%
Revenue growth 3Y8.19%
Revenue growth 5Y11.77%
Sales Q2Q%8.08%

3.2 Future

  • The Earnings Per Share is expected to grow by 39.31% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 17.92% on average over the next years. This is quite good.
EPS Next Y49.5%
EPS Next 2Y48.39%
EPS Next 3Y35.81%
EPS Next 5Y39.31%
Revenue Next Year13.46%
Revenue Next 2Y22.45%
Revenue Next 3Y19.46%
Revenue Next 5Y17.92%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IPA Yearly Revenue VS EstimatesIPA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M
IPA Yearly EPS VS EstimatesIPA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 0.5 -0.5 1 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • IPA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year IPA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IPA Price Earnings VS Forward Price EarningsIPA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IPA Per share dataIPA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2

4.3 Compensation for Growth

  • IPA's earnings are expected to grow with 35.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.39%
EPS Next 3Y35.81%

More info and screens

0

5. Dividend

5.1 Amount

  • IPA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMUNOPRECISE ANTIBODIES LTD

NASDAQ:IPA (9/3/2025, 8:24:29 PM)

After market: 2.12 +0.05 (+2.42%)

2.07

+0.14 (+7.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)09-11
Earnings (Next)12-08
Inst Owners8.61%
Inst Owner Change0%
Ins Owners1.19%
Ins Owner ChangeN/A
Market Cap95.53M
Revenue(TTM)24.52M
Net Income(TTM)-30.23M
Analysts80
Price Target5.1 (146.38%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)44.31%
Min EPS beat(2)0.99%
Max EPS beat(2)87.62%
EPS beat(4)3
Avg EPS beat(4)14.95%
Min EPS beat(4)-35.01%
Max EPS beat(4)87.62%
EPS beat(8)6
Avg EPS beat(8)14.05%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-9.96%
Min Revenue beat(2)-12.4%
Max Revenue beat(2)-7.52%
Revenue beat(4)0
Avg Revenue beat(4)-12.13%
Min Revenue beat(4)-22.81%
Max Revenue beat(4)-5.81%
Revenue beat(8)3
Avg Revenue beat(8)-4.97%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)25%
PT rev (3m)25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-10%
EPS NY rev (1m)-36.36%
EPS NY rev (3m)-36.36%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.34%
Revenue NY rev (1m)-0.6%
Revenue NY rev (3m)-0.6%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.4
P/FCF N/A
P/OCF N/A
P/B 5.6
P/tB 9.23
EV/EBITDA N/A
EPS(TTM)-0.22
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS0.38
BVpS0.37
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -68.03%
ROE -127.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 55.25%
FCFM N/A
ROA(3y)-49.16%
ROA(5y)-35.25%
ROE(3y)-84.68%
ROE(5y)-57.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.87%
GM growth 5Y-0.67%
F-Score4
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0.49
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.61%
Cap/Sales 3.26%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.08
Quick Ratio 1.85
Altman-Z -0.35
F-Score4
WACC10.11%
ROIC/WACCN/A
Cap/Depr(3y)20.78%
Cap/Depr(5y)25.53%
Cap/Sales(3y)5.4%
Cap/Sales(5y)5.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.55%
EPS Next Y49.5%
EPS Next 2Y48.39%
EPS Next 3Y35.81%
EPS Next 5Y39.31%
Revenue 1Y (TTM)0.01%
Revenue growth 3Y8.19%
Revenue growth 5Y11.77%
Sales Q2Q%8.08%
Revenue Next Year13.46%
Revenue Next 2Y22.45%
Revenue Next 3Y19.46%
Revenue Next 5Y17.92%
EBIT growth 1Y12.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-27.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-50.97%
OCF growth 3YN/A
OCF growth 5YN/A

IMMUNOPRECISE ANTIBODIES LTD / IPA FAQ

What is the ChartMill fundamental rating of IMMUNOPRECISE ANTIBODIES LTD (IPA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to IPA.


What is the valuation status for IPA stock?

ChartMill assigns a valuation rating of 1 / 10 to IMMUNOPRECISE ANTIBODIES LTD (IPA). This can be considered as Overvalued.


Can you provide the profitability details for IMMUNOPRECISE ANTIBODIES LTD?

IMMUNOPRECISE ANTIBODIES LTD (IPA) has a profitability rating of 1 / 10.


What is the financial health of IMMUNOPRECISE ANTIBODIES LTD (IPA) stock?

The financial health rating of IMMUNOPRECISE ANTIBODIES LTD (IPA) is 2 / 10.